Skip to main content
URGN $29.79 -0.27%
URGN logo
URGN · UroGen Pharma Ltd.
Track URGN — free
$29.79 -0.08 (-0.27%) At close · Nov 18 Play latest call Q3 2026 earnings call transcript
Market Cap
$1.46B
Shares
49.05M
Volume · Nov 18 1.14M Avg daily vol (3M) 1.09M
All webcasts

Conference · 2026-11-10

UroGen Pharma Ltd. (URGN) November 10, 2026 Conference Transcript

Concluded Nov 10, 2026 Audio replay Verified speakers
Nov 10, 2026 25:32 37 turns
Period
2026-11-10
Runtime
25:32
Sources
2 artifacts

Transcript & audio

Verified speakers 25:32 Audio
Speaker 0

All right, so welcome to this next Fireside Chat with Eurogen Pharma. It's my great pleasure to welcome Liz Barnett, President and CEO, as well as Chris Dagnan, Chief Financial Officer. Welcome.

Thanks for joining us today. Thanks. Thanks for having us.

Speaker 0

So, Liz, Eurogen is in a very important phase of a company's life cycle, sort of completing the early stages of the Susturi launch. You're expanding your pipeline. Why don't we start with just a big picture question? And so how do you think Eurogen is positioned heading into 2027?

Yeah, great question, obviously. Happy to be here and sharing our story. And it has been, you know, a long story past, right, getting to where we are today. But what an exciting time for us as a company. To your point, we launched our bladder cancer drug about a year ago, but got our permanent J code at the beginning of this year. So we really see this as our first year launch. And it's just been an exciting time for us. It's been a great year in the launch of Sesturi. We have a smaller drug called Gelmito that's on the market. So we have two commercial products. But to your point, we also have a pipeline. And we're excited about where we're going, both as leaders in urothelial cancers, but also developing a long-term sustainable growth company. And, you know, we've settled on our strategic plan with our board, excited about the fact that we not only see great growth in the near term, but we also see a path to continued leadership and growth for the long term. So, you know, that's what we're here to do. We're here to build a long-term sustainable growth company, both for patients, impacting patients, and for our shareholders to be able to see that we can continue to grow, you know, for the long haul. So, again, exciting time for our company as we shift from really a clinical stage to a commercial and clinical stage company. So that's sort of how we're looking as we get into 2027 and beyond.

Speaker 0

Yeah. Maybe a few questions on this story. So the permanent J-code has had a real impact on uptake and growth trajectory early this year. As you stand today, and you just reported third-quarter earnings recently, maybe comment a bit about how has the storage been adopted? What types of patients are using the drug in the life cycle of an MIBC patient? And what are the main drivers of additional growth?

Yeah, sure. I'll ask Chris to start, and I'll comment at commentary.

Yeah, so you mentioned the J-code. The J-code is certainly important here. And I think what's also important with the story is we're the first FDA-approved product in this space, right? So we are changing the treatment paradigm where urologists for these patients and what they're dealing with in the intermediate risk space is multiple recurrences. And so the patients will, you know, come in, they'll have the surgery, and then, unfortunately, a lot of these patients will constantly recur. And so, you know, for us, it's, one, getting urologists to understand the value proposition that we have in terms of... The clinical profile of the drug, but then also for them to understand, you know, how to change their practice in terms of getting them to use it from an operational workflow perspective, and then also confidence for them in terms of the reimbursement profile. And the good news for us is we have really strong reimbursement, with over 95% of covered lives having access to the drug. But urologists tend to be slower to adopt. They don't have a whole lot of familiarity with buy-in bill. And so for us, it's getting them, you know, to first try the product. And what they're typically doing is, They're trying it on one or two patients. They will see how it works from an operational perspective. They'll make sure they have the reimbursement, and then they start to expand their adoption. So we think about where we are for the launch. You know, we have 6,500 core targets that we're focused on. We're still in the early stages of getting them first to try the product. Through September this year, we have over 650 physicians that have now tried Sesturi. So we're making good progress, but we're still early in terms of getting physicians to try the drug. And then the other thing that we're really focused on is how many of these physicians become adopters or repeat writers. So once they get confidence in the profile of the drug, once they get confidence that they're getting reimbursed, as they would expect, starting to then treat multiple patients. And so we're also really pleased to see how many writers are becoming repeat writers. And so we're making good, steady progress on both fronts.

Speaker 0

What are you seeing so far on repeat usage? It seems like a lot of growth is driven by adding new prescribers to your funnel, but what are you seeing in terms of reusing and the same docs?

Actually, I know you guys don't see this level of data, but the depth is what's been driving our revenue so far, and that is you do have this group of champions and real adopters who have adopted it for the majority of their patients. And it's your typical curve, right? You have those that are early adopters. They really buy into it. They say, this is the way I'm going to treat my patients, and they adopt it for the majority of their patients. And then you have others on the other end that Chris was talking about that either haven't tried it yet or, oh, I'm going to try it on one patient and make sure that all of the things go right before I do. And so the good news is that the early adopters are driving debt. And so our revenue so far has come from a lot of these big adopters. And so as we go forward, we'll continue to do that. But we need to continue to get the breadth of users because, as Chris said, we only have 660 out of the 6,000. So still a long way to go there. And look, as we drive into 2027, not only are we engaging the patients, ensuring that physicians try the medicine, because 100% of the docs in our ATU that tried it said they will use it again. And so we have to make sure that they are helping them to identify these patients and really going from trialist to true adopters. Right.

Speaker 0

And so in the third quarter, you reported 68 million sales on 35% growth. Can you comment on how much of that was driven by new prescriptions versus repeat use?

No, you want to talk about that?

Yeah, so I think it's both, and that's where we are in this stage of the launch, right? We talk about the fact, again, that we think, you know, just given the urologists are a little bit slower to adopt, that we expect this to kind of be a steady growth trend over the launch of the drug. And so we think about this as, you know, a four- to five-year time to peak as opposed to maybe a more accelerated growth curve that you would see in the oncology space, you know, two to three years to peak. And so part of that is just, you know, steadily adding, and I think you're seeing that in the KPIs, steadily adding new writers. So we went from, you know, just over 450 prescriber, unique prescribers, through Q2 to over 650 in Q3. So we've done a nice job of continuing to add, but again, plenty more prescribers, too, as we think about growth. But then also, you know, as we think about how many of those writers were repeat writers, 45% of our prescriber base. Through Q2 or repeat writers, that's grown to 50%. So we think, importantly, as we grow this brand over time, we need to continue to add breadth of writers and then continue to drive further depth of penetration within those writers.

Speaker 0

Great. And in terms of what you're hearing back in clinical practice right now, how many patients or docs complete all six installations?

The majority. Almost all of them do. Okay.

Speaker 0

And any read on what real-world durability looks like relative to the study experience?

Still early, right, for durability, but I will tell you that we have seen and heard, and this is anecdotal information, but the ATU that we did, like I said, where 100% of the doctors said that they would use it again, I will say you've had doctors pleasantly surprised that even in these heavily pretreated patients, they're seeing good responses, either complete responses, or near-complete responses. And that is actually what helps, right? They see that. They see that as actually working, and that's making a big difference. So their real-world usage is mirroring what we showed in the clinical study.

Speaker 0

Okay, great. And then in the past, you talked about this of 1 billion peak sales opportunity with a 20% market penetration. Do you still, are you still confident in that estimate? And yeah, I think you mentioned the four to five years to peak. I guess what has to happen to get there?

Yeah, so the four to five years is really since the J code, right? So going back to January, we absolutely still believe in the billion plus peak. As I said, when you think about it from a penetration perspective, and we absolutely believe that there's an opportunity. Is there an opportunity to do better? Yes. You know, we've talked about a billion plus, and what we're trying to do is to help everybody understand that even though we are changing the way doctors practice medicine, we do think this is a better way to treat patients. And so as urologists start to adopt, we think we can, that billion dollars. And I think, frankly, our trend to date is already showing that, right?

Speaker 0

Yeah, and then obviously, you guys were the first product, the first, you know, systemic product on the market for intermediate risk and MIBC. There's obviously other people working on products, J&J, CT Oncology, for example, have data readouts soon. And so how do you envision the landscape evolving longer term and the use case for the story?

Unfortunately, I've been around for a really long time, so I've spent the last 30 years in oncology, and what sort of surprises me in the bladder cancer space is you hear it's highly competitive, it's highly competitive. Actually, it isn't. When you look at lung cancer, look at prostate cancer, look at how many in kidney cancer, drugs that there are, what you see when you have multiple entrants is a few things. One, it grows the market. I don't think you could show me an analog that shows that it doesn't grow the market when you have multiple players. The second thing is we're trying to get surgeons either to not do surgery in our case and use our drug instead or to use drugs in addition to surgery. Having multiple companies out there talking to physicians about changing the way they practice is actually going to help us all. And I think one of my biggest frustrations is this idea of a zero-sum game. It's not a zero-sum game. And we've talked about, like you said, our billion dollars. It's not a huge market share that you have to get to get to that billion plus. There's plenty of room for multiple players in this space. And somebody coming in, I think, actually helped. And I've said that, been saying that, you know, for the last couple of years, actually grows the market. And you see more and more physicians change the way they practice. So I'm excited about the fact, frankly, that there's more drugs coming in. I'm also happy for patients because, unfortunately, none of these are cures, and patients, while we are getting great durability with our drug, others, you know, coming in, you're going to cycle through multiple therapies, and that's what happens in other cancers as well, right? You cycle through therapies, and that's a good thing for patients. We believe that Zesturi and UGM-103 has a very compelling value proposition, even in comparison to the competition. We are the only ones that are non-surgical. So we are the only ones that we have an approval, and frankly, no one else is coming for a while. So we're still the only ones out there for quite a way in the future. But when they do, we're the only ones that offer a non-surgical option. So when you look at our data, 80% complete response rate, 80% of those patients still in response at a year, and 36 months, we still haven't reached the median. When you think about that type of data, and you're treating a patient for six weeks, and they're done. No surgery, six weeks. So the idea of being able to offer a patient not only recurrence-free living, but treatment-free living, everybody else coming into this space, the low-grade space, you're treating them for a longer period of time. And by the way, you're doing surgery first. So when you think about even the efficacy that you're seeing as they share their data, remember that it is an additional surgery, whereas ours is just us alone.

Speaker 0

One thing I've heard from investors is, oh, if... One of those products is being used in the adjuvant setting, including new patients up front. Does that reduce the flow through? Does it shrink the pie from the market, essentially?

Yeah, look, I call that cross-line reduction. You know, it's like when you use it in first line, so newly diagnosed. It doesn't impact it for a really long time. I think what everybody needs to remember is there's 400,000 people living in the U.S. with low-grade bladder cancer. In any given year, about 15% of them will recur, and that's where we get our patient population. Anybody who gets used in the newly diagnosed space, it will take that you'd have to have 100% penetration and newly diagnosed for many years for that number to go down. Because you're taking these 60,000 out of a 400,000 person prevalent pool. So as they move from this newly diagnosed into the prevalent pool, right, you still have that. So it doesn't impact it. And Mark Schomburg is our chief medical officer. He's here. And what he'll tell you, and we've seen it as well, is not everybody who's newly diagnosed. The current standard of care is just surgery, right? Right. And you're particularly for low grade, you're going to most of doctors will say, look, I'm going to do the surgery. I'll see how it goes. If they recur, then I'll use, you know, I only have about 20 percent who do more than just surgery in the initial. And that may grow. Right. As others come in in the newly diagnosed space. But it's not going to impact the number of patients available to us in the recurrent setting. You'd have to do 10 to 20 years for that to start to happen.

Speaker 0

Right. OK. Super helpful. All right. And then I had a question on UGN 103, which is your next-gen product candidate. And just remind us how that will be used to manage the lifecycle of the story and how you will transition patients to the product. Yeah, you want to talk about that?

Yeah. So, you know, UGN 103 offers a couple of operational and then also manufacturing enhancements. It's a more soluble product. It's a different excipient. And so, you know, our product needs to be mixed with our gel. So it allows the hospitals that buy the drug to be able to mix it more efficiently. The other thing is once it's been mixed, it's more stable. And so right now, once it's been mixed, and for community practices, we mix it for them and then ship it just in time. They have to instill within seven days. And so with the new product, it'll be several weeks, shelf life once reconstituted. So it'll give the community practices some more operational flexibility. Also, the other important part is just if we think about supply efficiency and capacity, it can be manufactured much more quickly. So we can lyophilize this drug product in three days versus, you know, currently our formulation takes about three weeks. So that will have some slight COGS benefit, but more importantly, just supply flexibility and efficiency. So those are, you know, some big components there. The other piece is, you know, 103 does have additional intellectual property associated with it. So both Zestorium 103 have a newly issued method of use patent that goes all the way out to July of 2044. One of three also has composition of matter for the proprietary mitomycin that goes to mid-2035, and it also has a separate patent with our RT gel that goes all the way through 2041, so, you know, good, strong protection around one of three, and for all the operational, you know, enhancements we talked about as well as the IP, you know, we're now taking one of three beyond intermediate risk, and we're, you know, like we talk about it, but now moving that into a high-risk papillary study Later this year.

Speaker 0

Yes, that's a good segue to my next question. So, yeah, talk about that high-risk papillary opportunity and also the competitive landscape and how it might fit in.

Yeah, I have the same sort of perspective as when we talk about the, you know, multiple players in the low-grade space. High-grade is obviously more critical for patients. So these patients, unfortunately, a lot of them used to lose their bladder because you had to take the bladder out to ensure that they didn't progress the muscle invasion. With new therapies coming in, that allows these patients to have therapy and continue to keep their bladder intact, and that's very important. You can imagine for the elderly patient, but even for younger patients, have to go through life without their bladder. So it's a very important and critical time. We believe that there's an opportunity. There's about 20,000 patients in the papillary-only area. And again, as I mentioned before, because none of these are cures, they'll cycle through multiple medicines. You know, I think that the data we've shown in IR and data that has been shown in the high-grade space with using traditional chemotherapies shows that they do work in this patient. And so that gives us high confidence, along with J&Js and Lexo, also a very similar approach. You know, we chose mitomycin, they chose gemcitabine, but the idea of being able to have this longer dwell time for a high-grade patient, and, you know, we believe that there's a lot of room in that space for multiple therapies, and we also have not only UGM-103 in that space, and we'll study it not just in papillary, but we look to study it across all the type of patients in high-grade because we believe that it will work in that space as well. Also, we're excited about expanding beyond. So we talk about the billion dollars in IR, then you have to add the opportunity, which is a similar opportunity, frankly, in the high-grade space. So that adds to our long-term growth strategy and positioning of UGN 103 slash Sesturi, right, where we are now. And again, I think it's a great thing for patients. Physicians are excited about seeing multiple therapies, and we see an opportunity. Not only for UGN-103 in that space, but also for UGN-501, which is our own next generation oncolytic virus that we just announced. We dosed our first patient in our phase one study, so excited about that as well.

Speaker 0

Yeah, that's another good segue just on 501. Yeah, maybe talk about, you know, the mechanism here, how valid is that, and what are the opportunities that you could pursue?

Yeah, you know, when we purchased the UGN501 from Econivir, it's important to note that Econivir had been studying it systemically in other tumors, not in bladder cancer, but they had done some preclinical work in bladder cancer, so we understood that it worked. What's interesting about UDN501 is it has sort of a dual mechanism. And so it has direct tumor lysis. So it kills tumors directly and elicits an immune response. So you kind of get this one-two punch, and that's differentiated versus other oncolytic viruses that are out there. So we believe that we'll be better, more potent. We have to prove that and demonstrate that out in clinical trials, which is what we've done. In addition to that, we're studying it in our gel. And the reason we're doing that is the same reason we use it with our current drugs is the ability to have them dwell longer. So kill more of the tumor cells and elicit more of a response, we believe, can be a very positive thing. And because it's being delivered locally, you don't see the same systemic side effects that you see if you delivered it from a systemic standpoint. And then lastly, I'll just say with UGN501, it also gives our company a bridge outside of bladder cancer, because we know it works in other cancers. So some onkylative viruses don't work across multiple cancers, but we know that this one does because of the work that Econovir did. And so we're looking at doing an intratumorally in other cancers. So bridge our company outside of just being in urothelial cancers, also to other specialty cancers.

Speaker 0

Very interesting. And then maybe just a commercial question. So, John Mido had a little bit of a weak quarter and a third. So, what happened then? What's going on in the market for John Mido, and how could that return back to growth?

Yeah, I'll let Chris talk about kind of where we are now, and then we'll talk a little bit about our plan to bring that back to growth.

Yeah, so just in the quarter, a couple of dynamics. So one, you know, we did have a one-off unexpected gross to net adjustment that we had in the quarter. So, you know, CMS has a discarded drug provision, and gel mito, there's, you know, some waste is associated with the administration of that drug. We got an invoice that went all the way back to 2024, unexpected, that, you know, basically created a $1.5 million one-time charge that put some pressure in the quarter. The other thing we're seeing in the space, we talked about how big the bladder cancer opportunity is. Gelmito is a smaller rare disease indication, right? I mean, you're talking about 6,000 patients in the U.S., and interestingly, there's a lot of recent competitive interest in this space in terms of new trials that have begun enrolling specifically in the U.S. in UTUC, and so beyond just our 104 program, which is the next-gen formulation of gelmito, and we're enrolling Patients expect to complete enrollment in either this quarter or early next. There's other companies that are also enrolling a lot of trials. And so when you're talking about a rare disease indication and these patients enrolling in a trial versus using gel mito, that has certainly put some additional pressure on our revenue profile.

Yeah, and if you think about it, just from our UGN-104 study, where we're rolling about 50% of our patients in the U.S., it's a hit of about $3.5 to $4 million for the year against Jalmito. That was a decision. We knew that that was a risk, but frankly, for the longer term, it was the right decision. And so if you just took just our own clinical study and then the one and a half million, you're getting closer to where we had guided in the beginning of the year for gel mito. And so we believe that there's still that opportunity. What are we doing to ensure that we return back to growth is we're putting together what we call a strike team for gel mito. Because, look, it is very similar to most drugs out there, promotionally sensitive. And we made the decision to prioritize Asturie, and we still think that was the right decision. And, you know, you can see just by what we've been able to deliver in Asturie this year, we entered the year, the analysts' consensus, it was 140 million, as I said, and we've hit 147 million in the three quarters with Asturie. So I think we've over-delivered in that area, but we, you know, we lost some focus on Jomaito, and so what we really have learned is you really do need some specific focus for Jomaito, and so we're putting together a 15-person, what we're calling, again, strike team that's only going to be focused on Jomaito, and hopefully in 2027 see that. We'll continue to have some pressure from clinical studies, but hopefully continue to see that growth because 104 will be fully enrolled no later than the beginning of 2027, so we won't have that direct pressure.

Speaker 0

Okay, great. And then last question. With your, you know, OPEX guidance as it stands, how confident are you could potentially reach profitability without raising additional capital?

Yeah, so we are right on the cost. If you looked, our net loss was $1.5 million in Q3, and with, one, the expected continued growth of this story, you know, as well as in Q3, we also had some one-time costs. For example, the $5 million PDUFA fee that we had for the 103 NDA filing, we expect to be profitable in the fourth quarter of this year. And importantly, we also expect to be cash flow positive in the fourth quarter of this year. So we have the resources we need to and through profitability.

Speaker 0

Great. Well, that's a good time to wrap up. Liz, I really appreciate the time today.

Of course.

Speaker 0

Thank you. Thanks. Appreciate it. Thank you. Appreciate it.

Full-screen source Call document